Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial PharmaTimesBoehringer Ingelheim reports significant reductions in weightMetabolic & GLP-1Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) PharmaTimes Boehringer Ingelheim reports significant reductions in weight Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Avalyn, in pursuit of better lung drugs, banks $300M in an IPONext: Ray Therapeutics receives EMA PRIME status for gene therapy Related Stories Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026 Clinical Data Key pipeline drug for Lundbeck delivers in Cushing syndrome pharminent June 15, 2026
